会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • Method Of Treating Viral Infections
    • 治疗病毒感染的方法
    • US20070202078A1
    • 2007-08-30
    • US10568176
    • 2004-08-03
    • Howard Smith
    • Howard Smith
    • A61K38/21A61K31/7056
    • A61K45/06A61K31/7056A61K38/21A61K38/212A61K2300/00
    • A method of pharmaceutical therapy includes co-administering: (A) interferon or derivative thereof with a low dose of B ribavirin ≦400 mg/day or ≦6 mg/kg/day), or related compound, where (B) provides a clinically effective blood level in portal circulation but less than clinically effective blood level in peripheral circulation, thereby providing a systemic effect of interferon throughout the body but a selective effect of ribavirin in the liver. The method also provides for co-administration of (A) with a high dose of (B) (preferably 400-800 mg/day) where (B) is administered as a slow-release formulation to provide a sustained virologic response and reduced side effects. The method also provides for co-adminstering (C) antioxidant or other membrane protective agent with both interferon and ribavirin such that the hepatoprotective activity of (C) complements the virucidal effect of interferon and ribavirin. (C) may be administered as a systemic or low-dose, slow-release, liver-selective formulation.
    • 一种药物治疗方法包括:(A)低剂量B利巴韦林= 400mg /天或<= 6mg / kg /天的干扰素或其衍生物或相关化合物,其中(B)提供 在门静脉循环中具有临床有效的血液水平,但低于周围循环中临床有效的血液水平,从而在整个身体中提供干扰素的全身作用,但是利巴韦林在肝脏中的选择性作用。 该方法还提供(A)与高剂量(B)(优选400-800mg /天)的共同给药,其中(B)作为缓释制剂施用以提供持续的病毒学应答和减少的侧面 效果。 该方法还提供了(C)抗氧化剂或其他膜保护剂与干扰素和利巴韦林的共同管理,使得(C)的肝保护活性补充了干扰素和利巴韦林的杀病毒作用。 (C)可以作为全身或低剂量,缓释,肝选择性制剂施用。